• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PIOGLITAZONE Drug Record

  • Summary
  • Interactions
  • Claims
  • PIOGLITAZONE chembl:CHEMBL595 Approved

    Alternate Names:

    DUETACT
    U-72107
    ACTOS
    AD-4833
    PIOGLITAZONE
    (+-)-5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-2,4-THIAZOLIDINEDIONE
    PIOGLITAZONA
    U-72107A
    5-{4-[2-(5-ETHYLPYRIDIN-2-YL)ETHOXY]BENZYL}-1,3-THIAZOLIDINE-2,4-DIONE
    XAB907
    ZACTOS
    PIOGLITAZONUM
    chemidplus:111025-46-8
    drugbank:01132
    pubchem.compound:4829
    rxcui:33738
    chembl:CHEMBL595

    Drug Info:

    Year of Approval 1999
    Drug Class hypoglycemic agents
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antidiabetic
    (3 More Sources)

    Publications:

    Kajosaari et al., 2006, Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide., Eur. J. Clin. Pharmacol.
    Stuart et al., 2007, Overexpression of GLUT5 in diabetic muscle is reversed by pioglitazone., Diabetes Care
    Blüher M et al., 2003, Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes., Diabetes Care
    Choi J et al., 2010, 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists., Bioorg Med Chem
    Nazreen S et al., 2014, Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression., Bioorg Med Chem Lett
    Usui S et al., 2005, Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2., Bioorg Med Chem Lett
    MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
    Sugii et al., 2009, PPARgamma activation in adipocytes is sufficient for systemic insulin sensitization., Proc. Natl. Acad. Sci. U.S.A.
    Spiegelman, 1998, PPAR-gamma: adipogenic regulator and thiazolidinedione receptor., Diabetes
    Willson et al., 1996, The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones., J. Med. Chem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Miyazaki et al., 2004, Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients., J. Clin. Endocrinol. Metab.
    Lehmann et al., 1995, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)., J. Biol. Chem.
    Otto et al., 2006, Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels., J. Endocrinol. Invest.
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Konturek et al., 2003, Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat., Eur. J. Pharmacol.
    Yin SJ et al., 2017, Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals., Pharmacogenet Genomics
    Jia et al., 2007, [Effects of pioglitazone on the morphology and the expression of connective tissue growth factor of transforming growth factor beta-induced rat hepatic stellate cells in vitro]., Zhonghua Gan Zang Bing Za Zhi
    Wang et al., 2006, [Effects of pioglitazone on MKP-1 and TSP-1 expression in early stages of diabetic retinopathy induced by streptozotocin]., Zhejiang Da Xue Xue Bao Yi Xue Ban
    Kiaei et al., 2005, Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis., Exp. Neurol.
  • PIOGLITAZONE   THBS1

    Interaction Score: 1.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17063547


    Sources:
    NCI

  • PIOGLITAZONE   ADIPOQ

    Interaction Score: 0.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PIOGLITAZONE   PTPRD

    Interaction Score: 0.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PIOGLITAZONE   SLC2A1

    Interaction Score: 0.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17251278


    Sources:
    NCI

  • PIOGLITAZONE   GHRL

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16682836


    Sources:
    NCI

  • PIOGLITAZONE   PPARG

    Interaction Score: 0.55

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name pioglitazone HCl,Actos
    Novel drug target Established target
    Trial Name pioglitazone/metformin,Actoplus Met, Competact

    PMIDs:
    12610044 21030263 24890090 15745794 16680159 20018750 9568680 8576907 11752352 15356026 7768881


    Sources:
    DTC TdgClinicalTrial TEND PharmGKB TTD

  • PIOGLITAZONE   GFAP

    Interaction Score: 0.33

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15649489


    Sources:
    NCI

  • PIOGLITAZONE   HSPA4

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12871756


    Sources:
    NCI

  • PIOGLITAZONE   TGFB1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17407709


    Sources:
    NCI

  • PIOGLITAZONE   CYP3A5

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • PIOGLITAZONE   G6PD

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PIOGLITAZONE   NR1I2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PIOGLITAZONE   YES1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PIOGLITAZONE   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28099407


    Sources:
    PharmGKB

  • PIOGLITAZONE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16447051


    Sources:
    NCI

  • TEND: PIOGLITAZONE

    • Version: 01-August-2011

    Alternate Names:
    PIOGLITAZONE Primary Drug Name

    Drug Info:
    Drug Class hypoglycemic agents
    Year of Approval 1999

    Publications:

  • TdgClinicalTrial: PIOGLITAZONE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antidiabetic
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: PIOGLITAZONE

    • Version: 14-September-2017

    Alternate Names:
    C29367 NCI drug code

    Drug Info:

    Publications:
    Otto et al., 2006, Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels., J. Endocrinol. Invest.
    Konturek et al., 2003, Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, accelerates gastric ulcer healing in rat., Eur. J. Pharmacol.
    Kajosaari et al., 2006, Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide., Eur. J. Clin. Pharmacol.

  • DTC: PIOGLITAZONE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL595 ChEMBL Drug ID

    Drug Info:

    Publications:
    Nazreen S et al., 2014, Thiazolidine-2,4-diones derivatives as PPAR-γ agonists: synthesis, molecular docking, in vitro and in vivo antidiabetic activity with hepatotoxicity risk evaluation and effect on PPAR-γ gene expression., Bioorg Med Chem Lett
    Usui S et al., 2005, Design, synthesis, and biological activity of novel PPARgamma ligands based on rosiglitazone and 15d-PGJ2., Bioorg Med Chem Lett
    Choi J et al., 2010, 1,3-Diphenyl-1H-pyrazole derivatives as a new series of potent PPARγ partial agonists., Bioorg Med Chem

  • PharmGKB: pioglitazone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Yin SJ et al., 2017, Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals., Pharmacogenet Genomics
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Blüher M et al., 2003, Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes., Diabetes Care

  • TTD: Pioglitazone

    • Version: 2020.06.01

    Alternate Names:
    D03OFF TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL595

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21